Manifestation and therapies of EGFRI-induced dermatological toxicities
10.3969/j.issn.1000-8179.2017.13.323
- VernacularTitle:表皮生长因子受体拮抗剂相关皮肤不良反应表现及治疗进展
- Author:
Yanmei PENG
- Keywords:
epidermal growth factor receptor;
skin rash;
pruritus;
minocycline;
aprepitant;
Chinese medicine
- From:
Chinese Journal of Clinical Oncology
2017;44(13):673-676
- CountryChina
- Language:Chinese
-
Abstract:
In the past decades, the advent of molecular targeted agents has been a considerable breakthrough for cancer patients, ex-cept for traditional operation, chemotherapy, and radiotherapy. As a novel therapeutic method, molecular targeting treatment is im-portant in the field of medical oncology, in which epidermal growth factor receptor inhibitors (EGFRIs) have been widely used as target-ed agents. Dermatological toxicities are the common side effects associated with the EGFRIs. Diarrhea, weakness, and pneumonia can be observed. EGFRI-induced dermatological toxicities may disrupt the health-related quality of life and cause anticancer treatment dose adjustments or discontinuance. The dermatological toxicities mainly involve rash acneiform, pruritus, xerosis, paronychia, hair change, and skin hypersensitivity. Treatment recommendations from guidelines include antibiotics, corticosteroids, and antihista-mines, but their clinical therapeutic efficacy have not been proven. Therefore, oncologists and dermatologists are investigating effec-tive medication. This article reviews the advances in the study of the clinical manifestations and drug therapies of EGFRI-induced der-matological toxicities to provide reference for clinical practitioners.
